文献速递肝病

非酒精性脂肪性肝病患者的死亡与疾病进展模式及预测因素

Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-08-17

基于德国2011至2016年理赔数据回顾性分析458万余人,非酒精性脂肪性肝病患病率4.7%。非进展者、代偿性肝硬化、失代偿性肝硬化及肝细胞癌的纵向死亡概率分别为3.6%、18.7%、28.8%和68%。心血管疾病、2型糖尿病、高血压、肥胖和肾损害为死亡的独立预测因素。

要点

  • 非酒精性脂肪性肝病患病率4.7%,代偿性肝硬化、失代偿性肝硬化及肝细胞癌的纵向死亡概率分别为18.7%、28.8%和68%。
  • 非进展者5年累积进展发生率为10.7%,代偿性肝硬化患者为16.7%。
  • 心血管疾病、2型糖尿病、高血压、肥胖和肾损害为死亡的独立预测因素。

核心结论

  • 非酒精性脂肪性肝病患者严重诊断不足,死亡概率高且随疾病进展而增加。
  • 早期识别和有效管理以阻止或逆转纤维化对预防进展至关重要。

研究设计与样本

  • 回顾性分析德国Institut für angewandte Gesundheitsforschung数据库2011至2016年的理赔数据。
  • 数据库共4 580 434例患者,其中非酒精性脂肪性肝病患病率4.7%(n=215 655)。
  • 成人非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎患者分为非酒精性脂肪性肝病、非酒精性脂肪性肝病非进展者、代偿性肝硬化、失代偿性肝硬化、肝移植或肝细胞癌队列。
  • 计算各疾病严重度队列的纵向死亡概率和进展发生率,并进行多变量分析校正死亡风险。

主要发现

  • 非进展者占36.8%,代偿性肝硬化占0.2%,失代偿性肝硬化占9.6%,肝移植占0.0005%,肝细胞癌占0.2%。
  • 代偿性肝硬化、失代偿性肝硬化和肝细胞癌的合并症发生率显著高于非进展者。
  • 非进展者、代偿性肝硬化、失代偿性肝硬化和肝细胞癌的纵向死亡概率分别为3.6%、18.7%、28.8%和68%。
  • 非酒精性脂肪性肝病和代偿性肝硬化患者5年随访的累积进展发生率分别为10.7%和16.7%。
  • 死亡的独立预测因素包括心血管疾病、2型糖尿病、高血压、肥胖和肾损害。

临床怎么用

  • 早期识别和有效管理以阻止或逆转纤维化,是预防非酒精性脂肪性肝病进展的关键。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood. AIMS: To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a large, real-world cohort of NAFLD patients. METHODS: Claims data from the German Institut für angewandte Gesundheitsforschung database between 2011 and 2016 were analyzed retrospectively. Adult patients diagnosed with NAFLD and/or NASH were categorised as NAFLD, NAFLD non-progressors, compensated cirrhosis, decompensated cirrhosis, liver transplant or hepatocellular carcinoma (HCC). The longitudinal probability of mortality and incidence of progression were calculated for disease severity cohorts and multivariable analyses performed for adjusted mortality. RESULTS: Among 4 580 434 patients in the database, prevalence of NAFLD was 4.7% (n = 215 655). Of those, 36.8% were non-progressors, 0.2% compensated cirrhosis, 9.6% decompensated cirrhosis, 0.0005% liver transplant and 0.2% HCC. Comorbidity rates were significantly higher in compensated cirrhosis, decompensated cirrhosis and HCC compared with non-progressors. The longitudinal probability of mortality for non-progressors, compensated cirrhosis, decompensated cirrhosis and HCC was 3.6%, 18.7%, 28.8% and 68%, respectively. Independent predictors of mortality included cardiovascular disease, type 2 diabetes mellitus, hypertension, obesity and renal impairment. The cumulative incidence of progression in NAFLD and compensated cirrhosis patients was 10.7% and 16.7%, respectively, over 5 years of follow-up. CONCLUSION: NAFLD patients were severely under-diagnosed and had a high probability of mortality that increased with disease progression. Early identification and effective management to halt or reverse fibrosis are essential to prevent progression.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Canbay A, Kachru N, Haas JS, et al. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020. PMID: 33016540. doi:10.1111/apt.16016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。